Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 37 to 48 of 12569 entries
Sorted by: Best Match Show Resources per page
Bioabsorbable Bypass Grafts Biofunctionalised with RGD Have Enhanced Biophysical Properties and Endothelialisation Tested In vivo.

Frontiers in pharmacology

Antonova LV, Seifalian AM, Kutikhin AG, Sevostyanova VV, Krivkina EO, Mironov AV, Burago AY, Velikanova EA, Matveeva VG, Glushkova TV, Sergeeva EA, Vasyukov GY, Kudryavtseva YA, Barbarash OL, Barbarash LS.
PMID: 27252652
Front Pharmacol. 2016 May 25;7:136. doi: 10.3389/fphar.2016.00136. eCollection 2016.

Small diameter arterial bypass grafts are considered as unmet clinical need since the current grafts have poor patency of 25% within 5 years. We have developed a 3D scaffold manufactured from natural and synthetic biodegradable polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and...

Cite
Antonova LV, Seifalian AM, Kutikhin AG, et al. Bioabsorbable Bypass Grafts Biofunctionalised with RGD Have Enhanced Biophysical Properties and Endothelialisation Tested In vivo. Front Pharmacol. 2016;7:136doi: 10.3389/fphar.2016.00136.
Antonova, L. V., Seifalian, A. M., Kutikhin, A. G., Sevostyanova, V. V., Krivkina, E. O., Mironov, A. V., Burago, A. Y., Velikanova, E. A., Matveeva, V. G., Glushkova, T. V., Sergeeva, E. A., Vasyukov, G. Y., Kudryavtseva, Y. A., Barbarash, O. L., & Barbarash, L. S. (2016). Bioabsorbable Bypass Grafts Biofunctionalised with RGD Have Enhanced Biophysical Properties and Endothelialisation Tested In vivo. Frontiers in pharmacology, 7136. https://doi.org/10.3389/fphar.2016.00136
Antonova, Larisa V, et al. "Bioabsorbable Bypass Grafts Biofunctionalised with RGD Have Enhanced Biophysical Properties and Endothelialisation Tested In vivo." Frontiers in pharmacology vol. 7 (2016): 136. doi: https://doi.org/10.3389/fphar.2016.00136
Antonova LV, Seifalian AM, Kutikhin AG, Sevostyanova VV, Krivkina EO, Mironov AV, Burago AY, Velikanova EA, Matveeva VG, Glushkova TV, Sergeeva EA, Vasyukov GY, Kudryavtseva YA, Barbarash OL, Barbarash LS. Bioabsorbable Bypass Grafts Biofunctionalised with RGD Have Enhanced Biophysical Properties and Endothelialisation Tested In vivo. Front Pharmacol. 2016 May 25;7:136. doi: 10.3389/fphar.2016.00136. eCollection 2016. PMID: 27252652; PMCID: PMC4879758.
Copy Download .nbib Format: NLM
Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension.

Frontiers in pharmacology

Sasagawa S, Nishimura Y, Sawada H, Zhang E, Okabe S, Murakami S, Ashikawa Y, Yuge M, Kawaguchi K, Kawase R, Mitani Y, Maruyama K, Tanaka T.
PMID: 27375481
Front Pharmacol. 2016 Jun 07;7:142. doi: 10.3389/fphar.2016.00142. eCollection 2016.

Pulmonary arterial hypertension (PAH) is a heterogeneous disorder associated with a progressive increase in pulmonary artery resistance and pressure. Although various therapies have been developed, the 5-year survival rate of PAH patients remains low. There is thus an important...

Cite
Sasagawa S, Nishimura Y, Sawada H, et al. Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension. Front Pharmacol. 2016;7:142doi: 10.3389/fphar.2016.00142.
Sasagawa, S., Nishimura, Y., Sawada, H., Zhang, E., Okabe, S., Murakami, S., Ashikawa, Y., Yuge, M., Kawaguchi, K., Kawase, R., Mitani, Y., Maruyama, K., & Tanaka, T. (2016). Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension. Frontiers in pharmacology, 7142. https://doi.org/10.3389/fphar.2016.00142
Sasagawa, Shota, et al. "Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension." Frontiers in pharmacology vol. 7 (2016): 142. doi: https://doi.org/10.3389/fphar.2016.00142
Sasagawa S, Nishimura Y, Sawada H, Zhang E, Okabe S, Murakami S, Ashikawa Y, Yuge M, Kawaguchi K, Kawase R, Mitani Y, Maruyama K, Tanaka T. Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension. Front Pharmacol. 2016 Jun 07;7:142. doi: 10.3389/fphar.2016.00142. eCollection 2016. PMID: 27375481; PMCID: PMC4894905.
Copy Download .nbib Format: NLM
Soft TCPTP Agonism-Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine.

Frontiers in pharmacology

Ghisalberti CA, Borzì RM, Cetrullo S, Flamigni F, Cairo G.
PMID: 27375482
Front Pharmacol. 2016 Jun 03;7:147. doi: 10.3389/fphar.2016.00147. eCollection 2016.

A reparative approach of disrupted epithelium in obstructive airway diseases, namely asthma and chronic obstructive pulmonary disease (COPD), may afford protection and long-lasting results compared to conventional therapies, e.g., corticosteroids or immunosuppressant drugs. Here, we propose the polyamine spermidine...

Cite
Ghisalberti CA, Borzì RM, Cetrullo S, et al. Soft TCPTP Agonism-Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine. Front Pharmacol. 2016;7:147doi: 10.3389/fphar.2016.00147.
Ghisalberti, C. A., Borzì, R. M., Cetrullo, S., Flamigni, F., & Cairo, G. (2016). Soft TCPTP Agonism-Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine. Frontiers in pharmacology, 7147. https://doi.org/10.3389/fphar.2016.00147
Ghisalberti, Carlo A, et al. "Soft TCPTP Agonism-Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine." Frontiers in pharmacology vol. 7 (2016): 147. doi: https://doi.org/10.3389/fphar.2016.00147
Ghisalberti CA, Borzì RM, Cetrullo S, Flamigni F, Cairo G. Soft TCPTP Agonism-Novel Target to Rescue Airway Epithelial Integrity by Exogenous Spermidine. Front Pharmacol. 2016 Jun 03;7:147. doi: 10.3389/fphar.2016.00147. eCollection 2016. PMID: 27375482; PMCID: PMC4892113.
Copy Download .nbib Format: NLM
Modulation of Autophagy by Sorafenib: Effects on Treatment Response.

Frontiers in pharmacology

Prieto-Domínguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J, Mauriz JL.
PMID: 27375485
Front Pharmacol. 2016 Jun 08;7:151. doi: 10.3389/fphar.2016.00151. eCollection 2016.

The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces...

Cite
Prieto-Domínguez N, Ordóñez R, Fernández A, et al. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol. 2016;7:151doi: 10.3389/fphar.2016.00151.
Prieto-Domínguez, N., Ordóñez, R., Fernández, A., García-Palomo, A., Muntané, J., González-Gallego, J., & Mauriz, J. L. (2016). Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Frontiers in pharmacology, 7151. https://doi.org/10.3389/fphar.2016.00151
Prieto-Domínguez, Nestor, et al. "Modulation of Autophagy by Sorafenib: Effects on Treatment Response." Frontiers in pharmacology vol. 7 (2016): 151. doi: https://doi.org/10.3389/fphar.2016.00151
Prieto-Domínguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J, Mauriz JL. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol. 2016 Jun 08;7:151. doi: 10.3389/fphar.2016.00151. eCollection 2016. PMID: 27375485; PMCID: PMC4896953.
Copy Download .nbib Format: NLM
G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease.

Frontiers in pharmacology

Divorty N, Mackenzie AE, Nicklin SA, Milligan G.
PMID: 25805994
Front Pharmacol. 2015 Mar 10;6:41. doi: 10.3389/fphar.2015.00041. eCollection 2015.

G protein-coupled receptor 35 (GPR35) is an orphan receptor, discovered in 1998, that has garnered interest as a potential therapeutic target through its association with a range of diseases. However, a lack of pharmacological tools and the absence of...

Cite
Divorty N, Mackenzie AE, Nicklin SA, et al. G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front Pharmacol. 2015;6:41doi: 10.3389/fphar.2015.00041.
Divorty, N., Mackenzie, A. E., Nicklin, S. A., & Milligan, G. (2015). G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Frontiers in pharmacology, 641. https://doi.org/10.3389/fphar.2015.00041
Divorty, Nina, et al. "G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease." Frontiers in pharmacology vol. 6 (2015): 41. doi: https://doi.org/10.3389/fphar.2015.00041
Divorty N, Mackenzie AE, Nicklin SA, Milligan G. G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front Pharmacol. 2015 Mar 10;6:41. doi: 10.3389/fphar.2015.00041. eCollection 2015. PMID: 25805994; PMCID: PMC4354270.
Copy Download .nbib Format: NLM
Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors.

Frontiers in pharmacology

de Munnik SM, Smit MJ, Leurs R, Vischer HF.
PMID: 25805993
Front Pharmacol. 2015 Mar 09;6:40. doi: 10.3389/fphar.2015.00040. eCollection 2015.

Human herpesviruses (HHVs) are widespread infectious pathogens that have been associated with proliferative and inflammatory diseases. During viral evolution, HHVs have pirated genes encoding viral G protein-coupled receptors (vGPCRs), which are expressed on infected host cells. These vGPCRs show...

Cite
de Munnik SM, Smit MJ, Leurs R, et al. Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol. 2015;6:40doi: 10.3389/fphar.2015.00040.
de Munnik, S. M., Smit, M. J., Leurs, R., & Vischer, H. F. (2015). Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Frontiers in pharmacology, 640. https://doi.org/10.3389/fphar.2015.00040
de Munnik, Sabrina M, et al. "Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors." Frontiers in pharmacology vol. 6 (2015): 40. doi: https://doi.org/10.3389/fphar.2015.00040
de Munnik SM, Smit MJ, Leurs R, Vischer HF. Modulation of cellular signaling by herpesvirus-encoded G protein-coupled receptors. Front Pharmacol. 2015 Mar 09;6:40. doi: 10.3389/fphar.2015.00040. eCollection 2015. PMID: 25805993; PMCID: PMC4353375.
Copy Download .nbib Format: NLM
Antimicrobial, Anthelmintic Activities and Characterisation of Functional Phenolic Acids of Achyranthes aspera Linn.: A Medicinal Plant Used for the Treatment of Wounds and Ringworm in East Africa.

Frontiers in pharmacology

Ndhlala AR, Ghebrehiwot HM, Ncube B, Aremu AO, Gruz J, Šubrtová M, Doležal K, du Plooy CP, Abdelgadir HA, Van Staden J.
PMID: 26635604
Front Pharmacol. 2015 Nov 23;6:274. doi: 10.3389/fphar.2015.00274. eCollection 2015.

Achyranthes aspera Linn. (Amaranthaceae) commonly known as Prickly Chaff flower (English) is traditionally used for treating a number of ailments. Different parts of the plant are used in treating wounds and ringworm in East Africa and elsewhere for a...

Cite
Ndhlala AR, Ghebrehiwot HM, Ncube B, et al. Antimicrobial, Anthelmintic Activities and Characterisation of Functional Phenolic Acids of Achyranthes aspera Linn.: A Medicinal Plant Used for the Treatment of Wounds and Ringworm in East Africa. Front Pharmacol. 2015;6:274doi: 10.3389/fphar.2015.00274.
Ndhlala, A. R., Ghebrehiwot, H. M., Ncube, B., Aremu, A. O., Gruz, J., Šubrtová, M., Doležal, K., du Plooy, C. P., Abdelgadir, H. A., & Van Staden, J. (2015). Antimicrobial, Anthelmintic Activities and Characterisation of Functional Phenolic Acids of Achyranthes aspera Linn.: A Medicinal Plant Used for the Treatment of Wounds and Ringworm in East Africa. Frontiers in pharmacology, 6274. https://doi.org/10.3389/fphar.2015.00274
Ndhlala, Ashwell R, et al. "Antimicrobial, Anthelmintic Activities and Characterisation of Functional Phenolic Acids of Achyranthes aspera Linn.: A Medicinal Plant Used for the Treatment of Wounds and Ringworm in East Africa." Frontiers in pharmacology vol. 6 (2015): 274. doi: https://doi.org/10.3389/fphar.2015.00274
Ndhlala AR, Ghebrehiwot HM, Ncube B, Aremu AO, Gruz J, Šubrtová M, Doležal K, du Plooy CP, Abdelgadir HA, Van Staden J. Antimicrobial, Anthelmintic Activities and Characterisation of Functional Phenolic Acids of Achyranthes aspera Linn.: A Medicinal Plant Used for the Treatment of Wounds and Ringworm in East Africa. Front Pharmacol. 2015 Nov 23;6:274. doi: 10.3389/fphar.2015.00274. eCollection 2015. PMID: 26635604; PMCID: PMC4655238.
Copy Download .nbib Format: NLM
Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1.

Frontiers in pharmacology

Smith NJ.
PMID: 26635605
Front Pharmacol. 2015 Nov 17;6:275. doi: 10.3389/fphar.2015.00275. eCollection 2015.

Orphan G protein-coupled receptors (GPCRs) represent a largely untapped resource for the treatment of a variety of diseases, despite sophisticated advances in drug discovery. Two promising orphan GPCRs are the endothelin B receptor-like proteins, GPR37 [ET(B)R-LP, Pael-R] and GPR37L1...

Cite
Smith NJ. Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1. Front Pharmacol. 2015;6:275doi: 10.3389/fphar.2015.00275.
Smith, N. J. (2015). Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1. Frontiers in pharmacology, 6275. https://doi.org/10.3389/fphar.2015.00275
Smith, Nicola J. "Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1." Frontiers in pharmacology vol. 6 (2015): 275. doi: https://doi.org/10.3389/fphar.2015.00275
Smith NJ. Drug Discovery Opportunities at the Endothelin B Receptor-Related Orphan G Protein-Coupled Receptors, GPR37 and GPR37L1. Front Pharmacol. 2015 Nov 17;6:275. doi: 10.3389/fphar.2015.00275. eCollection 2015. PMID: 26635605; PMCID: PMC4648071.
Copy Download .nbib Format: NLM
Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia.

Frontiers in pharmacology

Hamdoun S, Jung P, Efferth T.
PMID: 28344555
Front Pharmacol. 2017 Mar 10;8:110. doi: 10.3389/fphar.2017.00110. eCollection 2017.

Multidrug resistance, a major problem that leads to failure of anticancer chemotherapy, requires the development of new drugs. Repurposing of established drugs is a promising approach for overcoming this problem. An example of such drugs is niclosamide, a known...

Cite
Hamdoun S, Jung P, Efferth T. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia. Front Pharmacol. 2017;8:110doi: 10.3389/fphar.2017.00110.
Hamdoun, S., Jung, P., & Efferth, T. (2017). Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia. Frontiers in pharmacology, 8110. https://doi.org/10.3389/fphar.2017.00110
Hamdoun, Sami, et al. "Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia." Frontiers in pharmacology vol. 8 (2017): 110. doi: https://doi.org/10.3389/fphar.2017.00110
Hamdoun S, Jung P, Efferth T. Drug Repurposing of the Anthelmintic Niclosamide to Treat Multidrug-Resistant Leukemia. Front Pharmacol. 2017 Mar 10;8:110. doi: 10.3389/fphar.2017.00110. eCollection 2017. PMID: 28344555; PMCID: PMC5344920.
Copy Download .nbib Format: NLM
Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research.

Frontiers in pharmacology

Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, Gould T, Hoffmaster K.
PMID: 25120485
Front Pharmacol. 2014 Jul 28;5:174. doi: 10.3389/fphar.2014.00174. eCollection 2014.

Characterizing the relationship between the pharmacokinetics (PK, concentration vs. time) and pharmacodynamics (PD, effect vs. time) is an important tool in the discovery and development of new drugs in the pharmaceutical industry. The purpose of this publication is to...

Cite
Tuntland T, Ethell B, Kosaka T, et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014;5:174doi: 10.3389/fphar.2014.00174.
Tuntland, T., Ethell, B., Kosaka, T., Blasco, F., Zang, R. X., Jain, M., Gould, T., & Hoffmaster, K. (2014). Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Frontiers in pharmacology, 5174. https://doi.org/10.3389/fphar.2014.00174
Tuntland, Tove, et al. "Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research." Frontiers in pharmacology vol. 5 (2014): 174. doi: https://doi.org/10.3389/fphar.2014.00174
Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, Gould T, Hoffmaster K. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014 Jul 28;5:174. doi: 10.3389/fphar.2014.00174. eCollection 2014. PMID: 25120485; PMCID: PMC4112793.
Copy Download .nbib Format: NLM
The IRP/IRE system in vivo: insights from mouse models.

Frontiers in pharmacology

Wilkinson N, Pantopoulos K.
PMID: 25120486
Front Pharmacol. 2014 Jul 28;5:176. doi: 10.3389/fphar.2014.00176. eCollection 2014.

Iron regulatory proteins 1 and 2 (IRP1 and IRP2) post-transcriptionally control the expression of several mRNAs encoding proteins of iron, oxygen and energy metabolism. The mechanism involves their binding to iron responsive elements (IREs) in the untranslated regions of...

Cite
Wilkinson N, Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014;5:176doi: 10.3389/fphar.2014.00176.
Wilkinson, N., & Pantopoulos, K. (2014). The IRP/IRE system in vivo: insights from mouse models. Frontiers in pharmacology, 5176. https://doi.org/10.3389/fphar.2014.00176
Wilkinson, Nicole, and Pantopoulos, Kostas. "The IRP/IRE system in vivo: insights from mouse models." Frontiers in pharmacology vol. 5 (2014): 176. doi: https://doi.org/10.3389/fphar.2014.00176
Wilkinson N, Pantopoulos K. The IRP/IRE system in vivo: insights from mouse models. Front Pharmacol. 2014 Jul 28;5:176. doi: 10.3389/fphar.2014.00176. eCollection 2014. PMID: 25120486; PMCID: PMC4112806.
Copy Download .nbib Format: NLM
A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects.

Frontiers in pharmacology

Rauf A, Uddin G, Siddiqui BS, Molnár J, Csonka Á, Ahmad B, Szabó D, Farooq U, Khan A.
PMID: 26732580
Front Pharmacol. 2015 Dec 16;6:293. doi: 10.3389/fphar.2015.00293. eCollection 2015.

Three new dimeric naphthoquinones, 5,4'-dihydroxy-1'-methoxy-6,6'-dimethyl-7,3'-binaphthyl-1,4,5',8'-tetraone (1), 5',8'-dihydroxy-5-methoxy-6,6'-dimethyl-7,3'-binaphthyl-1,4,1',4'-tetraone (2) and 8,5',8'-trihydroxy-6,6'-dimethyl-7,3'-binaphthyl-1,4,1',4'-tetraone (3), were isolated from the roots of Diospyros lotus. Their structures were elucidated by spectroscopic techniques, including 1D and 2D NMR, such as HSQC, HMBS, NOESY, and J-resolved. Compounds...

Cite
Rauf A, Uddin G, Siddiqui BS, et al. A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects. Front Pharmacol. 2015;6:293doi: 10.3389/fphar.2015.00293.
Rauf, A., Uddin, G., Siddiqui, B. S., Molnár, J., Csonka, �. �., Ahmad, B., Szabó, D., Farooq, U., & Khan, A. (2015). A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects. Frontiers in pharmacology, 6293. https://doi.org/10.3389/fphar.2015.00293
Rauf, Abdur, et al. "A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects." Frontiers in pharmacology vol. 6 (2015): 293. doi: https://doi.org/10.3389/fphar.2015.00293
Rauf A, Uddin G, Siddiqui BS, Molnár J, Csonka Á, Ahmad B, Szabó D, Farooq U, Khan A. A Rare Class of New Dimeric Naphthoquinones from Diospyros lotus have Multidrug Reversal and Antiproliferative Effects. Front Pharmacol. 2015 Dec 16;6:293. doi: 10.3389/fphar.2015.00293. eCollection 2015. PMID: 26732580; PMCID: PMC4679852.
Copy Download .nbib Format: NLM
Showing 37 to 48 of 12569 entries